Efficacy and safety of cinepazide maleate injection in acute ischemic stroke patients with obvious motor function deficit
10.3760/cma.j.cn113694-20211013-00704
- VernacularTitle:马来酸桂哌齐特注射液治疗合并明显肢体运动功能障碍的急性缺血性脑卒中患者的有效性和安全性
- Author:
Jun NI
1
;
Huisheng CHEN
;
Guofang CHEN
;
Yong JI
;
Fei YI
;
Zhuobo ZHANG
;
Yi YANG
;
Jin WU
;
Xueli CAI
;
Bei SHAO
;
Jianfeng WANG
;
Yafang LIU
;
Deqin GENG
;
Xinhui QU
;
Xiaohong LI
;
Yan WEI
;
Jianping DING
;
Hua LYU
;
Yining HUANG
;
Yonghua HUANG
;
Bo XIAO
;
Tao GONG
;
Liying CUI
Author Information
1. 中国医学科学院北京协和医院神经科，北京 100730
- Keywords:
Stroke;
Multicenter study;
Randomized controlled trial;
Movement disorders;
Cinepazide maleate;
Subgroup analysis
- From:
Chinese Journal of Neurology
2022;55(5):474-480
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To confirm the efficacy and safety of cinepazide maleate injection in acute ischemic stroke patients with obvious motor function deficit.Methods:This study is a subgroup analysis of multi-center, randomized, double-blind, placebo-controlled phase Ⅳ clinical trial. A total 812 patients of acute ischemic stroke with obvious limb motor deficit [motor function of limbs score in National Institutes of Health Stroke Scale (NIHSS) ≥4] were enrolled in this subgroup analysis. Patients received either cinepazide maleate injection or placebo. The treatment period was 14 days and follow-up was 90 days. The efficacy endpoints included the proportions of patients with a modified Rankin Scale (mRS) score ≤2, mRS score ≤1 and Barthel Index <95 on day 90. Safety was evaluated by recording all adverse events, monitoring vital signs, laboratory parameters and electrocardiogram.Results:A total of 732 patients were involved in the final efficacy analysis (361 in cinepazide maleate group and 371 in control group). The baseline limb motor function score of NIHSS was 5.23±1.43 in the cinepazide maleate group whereas 5.20±1.36 in the control group. Logistic regression analysis showed that following treatment for 90 days, the proportion of patients with a mRS score ≤2 was significantly higher in the cinepazide maleate group than in the control group [56.0% (202/361) vs 44.2% (164/371), OR=0.60, 95% CI 0.44-0.82, P=0.002]. The proportion of patients with a mRS score ≤1 was higher in the cinepazide maleate group than in the control group [43.3% (139/361) vs 35.2% (118/371), OR=0.69, 95% CI 0.50-0.97, P=0.031]. The proportion of patients with a Barthel Index <95 on day 90 was significantly lower in the cinepazide maleate group than in the control group [45.2% (145/361) vs 55.2% (185/371), OR=0.64, 95% CI 0.46-0.88, P=0.007]. During the treatment and follow-up period, the incidence of the most common adverse events in the cinepazide maleate group was 50.4% (199/395). Constipation and abnormal liver function were more common, but there were no statistically significant differences between the two groups. Conclusion:Cinepazide maleate injection is superior to placebo in improving neurological function and activities of daily living, reducing disability, and promoting functional recovery and safe in patients with acute ischemic stroke with obvious limb motor deficit.
